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A method of ﬂuorescent nanoparticle-based indirect immunoﬂuorescence microscopy (FNP-IIFM) was developed for the
rapid detection of Mycobacterium tuberculosis. An anti-Mycobacterium tuberculosis antibody was used as primary anti-
body to recognize Mycobacterium tuberculosis, and then an antibody binding protein (Protein A) labeled with Tris(2,2-
bipyridyl)dichlororuthenium(II) hexahydrate (RuBpy)-doped silica nanoparticles was used to generate ﬂuorescent signal for mi-
croscopic examination. Prior to the detection, Protein A was immobilized on RuBpy-doped silica nanoparticles with a coverage of
∼5.1×102 molecules/nanoparticle. With this method, Mycobacterium tuberculosis in bacterial mixture as well as in spiked sputum
was detected. The use of the ﬂuorescent nanoparticles reveals ampliﬁed signal intensity and higher photostability than the direct
use of conventional ﬂuorescent dye as label. Our preliminary studies have demonstrated the potential application of the FNP-IIFM
method for rapid detection of Mycobacterium tuberculosis in clinical samples.
Copyright © 2007 Dilan Qin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Tuberculosis (TB) is a global public health emergency,
fueled by the spread of human immunodeﬁciency virus
(HIV)/Acquired Immune Deﬁciency Syndrome (AIDS) and
the emergence of drug-resistant stains of Mycobacterium tu-
berculosis(M.tuberculosis).Approximately2billionpeople—
one third of the human population—are currently infected
with TB, with one new infection occurring every second.
Each year there are more than 8.8 million cases and close to
2 million deaths attributed to TB worldwide. Experts at the
World Health Organization (WHO) predicted these num-
bers would escalate in coming decades, nearly 1 billion peo-
ple would become newly infected, over 150 million would
become sick, and 36 million would die worldwide between
now and 2020—if control was not further strengthened [1].
Rapid and accurate diagnosis of tuberculosis is a critical step
in the management and control of TB. For decades, diag-
nosis has largely relied on acid-fast staining and culture of
bacilli. However, the sensitivity of acid-fast staining is poor,
and culture is a relatively time-consuming process. Many ef-
forts have been directed toward developing techniques for
rapiddiagnosisoftuberculosiswithhighersensitivityandre-
liability [2], including methods based on molecular biology
(molecular diagnosis techniques) [3], such as nucleic acid
ampliﬁcationtests(NAAtests)[4,5],DN Apr obes[6,7];and
methods based on immunology (serodiagnosis techniques)
[8], such as enzyme-linked immunosorbent assay (ELISA)
[9, 10], immunochromatographic assay [11], latex aggluti-
nation assay [12]. Recently, more simple, direct, and visually
detectable assays have been developed for rapid diagnosis of
TB with Au nanoparticles [13, 14]. These approaches have
contributed much on the improvement of sensitivity and ac-
curacy of the detection but still exhibit deﬁciencies in some
extent [15]. NAA tests have been the subject of a number of
investigations. Many commercial kits are available including
theAmplicorandMTDtestswhicharecurrentlyUSFDAap-
proved. The NAA tests have high speciﬁcity and work better
to rule-in TB. However, sensitivity of NAA tests is lower and
it is less good to rule-out TB. Serological tests for the diagno-
sis of tuberculosis have been attempted for decades. Dozens
of commercial kits are available, most of which are focused2 Journal of Biomedicine and Biotechnology
on antibody detection. However, assays based on antibodies
detection are hard to distinguish active TB from BCG vacci-
nationandpastinfection.Therefore,morestudiesareneeded
to develop and improve the detection methods for tubercu-
losis.
Dye-doped silica nanoparticles [16, 17], exhibiting such
important advantages as high luminescence and photosta-
bility compared to conventional ﬂuorescent dyes, have been
widely applied in biological imaging and ultrasensitive bio-
analyses, including cell staining [18], DNA detection [19,
20], cell surface receptor targeting [21–24], and ultrasensi-
tive detection of Escherichia coli O157:H7 [25]. Owing to the
dye-encapsulated structure, thousands of dye molecules em-
bedded in one nanoparticle contribute to the luminescence
of one particle, causing signiﬁcant signal ampliﬁcation. In
this paper, we establish a rapid immunological method for
detection of M. tuberculosis by combining highly lumines-
cent RuBpy-doped nanoparticles with indirect immunoﬂu-
orescence microscopy. Since direct anchoring of antibod-
ies onto solid supports via covalence methods is always
faced with the loss of activity of the antibodies, Protein A
was applied as an aﬃnitive adsorber. In order to obtain
full antibody activity, M. tuberculosis was ﬁrst recognized
with the speciﬁc antibody in solution then signaled by Pro-
tein A functionalized ﬂuorescent nanoparticles. This method
was used to detect M. tuberculosis in mixed bacterial sam-
ples and spiked sputum samples. Meanwhile, signal intensity
and photostability of the method were compared with con-
ventional ﬂuorescent dye ﬂuorescein isothiocyanate labeling
method.
2. MATERIALS AND METHODS
2.1. Bacteria
The H37Ra strain of M. tuberculosis was obtained from the
National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China). M. tuberculosis was
cultured by Dr. Songlin Yi (Hunan Tuberculosis Hospital,
Hunan, China) on modiﬁed Lowenstein-Jenson medium at
37
◦C for 3-4 weeks to obtain pure bacterial culture for use
in establishing detection method. M. tuberculosis was har-
vested in pH 7.4, 0.01M phosphate buﬀered saline (PBS)
to form predominantly single-cell suspension using pre-
viously described method [26]. E. coli strain DH5α (Mi-
crobial Culture Collection Center of Guangdong Institute
of Microbiology, Guangdong, China) was grown overnight
in Luria-Bertani broth at 37
◦C. The bacterial suspensions
were counted in a Petroﬀ-Hausser chamber, and the con-
centrations of bacteria were adjusted for use in experi-
ments.
2.2. Materials
Tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate (R-
uBpy), Triton X-100, ﬂuorescein isothiocyanate (FITC),
and Protein A from Staphylococcus aureus were purchased
from Sigma-Aldrich. Sodium carbonate, sodium bicar-
bonate, sodium dihydrogen phosphate, disodium hydro-
gen phosphate, sodium hydroxide, sodium citrate, acetoni-
trile, glycine, and N-acetyl-L-cysteine (NALC) of analytical
grade were obtained from China National Medicines Group
Shanghai Chemical Reagents Company (Shanghai, China).
CyanogenBromide(CNBr)wassynthesizedusingpreviously
described method [27]. Puriﬁed rabbit anti-M. tuberculo-
sis IgG and FITC-conjugated rabbit anti-M. tuberculosis IgG
were supplied by Biodesign International (Me, USA). Rabbit
anti-p53 IgG was purchased from Boster Biological Technol-
ogy (Wuhan, China).
2.3. Instrumentation
The morphology and uniformity of RuBpy-doped silica
nanoparticles were measured with an atomic force micro-
scope (AFM) SPI3800N-SPA400 (Seiko). Size distribution
analysisofRuBpy-dopedsilicananoparticleswasdetermined
at 25
◦C by dynamic light scattering (DLS) using Zetasizer
3000HSA (Malvern). The volume-weighted average diame-
ter obtained by the manufacturer’s software was used for the
calculation of the average nanoparticle volume. A refractive
index of 1.47 was used for nanoparticles (the refractive in-
dex of silica). Viscosity was determined at 30
◦C using a cone
plate digital viscometer LVDV-III+CP (Brookﬁeld). Deter-
mination of protein concentration according to the Bradford
method wasdone withaUV-Vis spectrophotometerDU-800
(Beckman) [28].
2.4. BiologicalmodiﬁcationoftheRuBpy-doped
silicananoparticles
RuBpy-doped silica nanoparticles were prepared using the
water-in-oil (W/O) microemulsion method that had been
described before [21]. In order to immobilize Protein A
onto the nanoparticles, the surface of the RuBpy-doped sil-
ica nanoparticles was ﬁrst activated with CNBr. Nanoparti-
cles (11.2mg) were suspended in 2ml of 2M sodium car-
bonate solution by ultrasonication. A solution of CNBr in
acetonitrile (0.78g of CNBr dissolved in 2ml of acetonitrile)
was then added dropwise to the particle suspension under
stirring at room temperature for 5 minutes. After the activa-
tion reaction, the particles were washed twice with ice-cold
water and twice with pH 7.4, 0.01M PBS buﬀer. For cova-
lently coupling of Protein A onto the nanoparticle surface,
a4 0 μl portion of aqueous solution of 2mg/ml Protein A
was added to 1ml of 1.1mg/ml freshly activated nanopar-
ticles in PBS, and stirring was continued for 24 hours at
4◦C. The Protein A immobilized nanoparticles were then
blocked with 6ml of 0.3M glycine solution (pH 8.0) 4◦Cf o r
16 hours in order to reduce the eﬀect of nonspeciﬁc bind-
ing in the subsequent immunoassay. The ﬁnal product was
washed, resuspended in PBS, and stored at 4◦Cf o rf u t u r e
usage. The surface coverage of Protein A on nanoparticles
was determined by measuring the decrease of Protein A con-
centration in the coupling solution by the Bradford method
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2.5. Indirectimmunoﬂuorescencedetectionof
M.tuberculosiswithbioconjugatednanoparticles
Rabbit anti-M. tuberculosis antibody was added to a 500μl
suspension of M. tuberculosis in PBS (antibody ﬁnal con-
centration: 5μg/ml) and incubated at 37
◦Cf o r1h o u r .
The suspension was subsequently washed with PBS twice.
Nanoparticle-Protein A conjugates (0.1mg/ml) were then
added, and the mixture was incubated at 37
◦Cf o r1h o u r .
To remove the free nanoparticle-Protein A conjugates that
did not bind to the bacteria, the mixture was centrifuged at
8000rpm for 2 minutes, and then the supernatant was dis-
card. The pellet was washed twice again. Smear slide was
madebyspreadingthepelletonglassslideandobservedwith
ﬂuorescence microscopy or confocal microscopy. For con-
trols, the rabbit anti-p53 antibody or PBS only was substi-
tuted for the primary antibody. Another bacterium E. coli
DH5α was treated with the same strategy to test the cross-
reaction with bioconjugated nanoparticles.
For immunoﬂuorescence detection of M. tuberculosis
with FITC-labeled antibody, the FITC-conjugated rabbit
anti-M. tuberculosis antibody was added to a 500μls u s p e n -
sion of M. tuberculosis in PBS (antibody ﬁnal concentration:
25μg/ml) and the mixture was incubated at 37
◦Cf o r1h o u r .
The suspension was subsequently washed with PBS for three
times and then spread on glass slide for microscopic exami-
nation.
2.6. Preparationofmixedbacterialsample
The mixed bacterial sample was prepared by mixing FITC-
labeled E. coli and unlabeled M. tuberculosis. The FITC-
labeled E. coli was ﬁrst obtained according to the follow-
ing method. E. coli was incubated at a concentration of 109
cells/ml with 0.5mg of FITC in 0.1M Na2CO3–NaHCO3
buﬀer (pH 9.2) at 37
◦C for 2 hours in the dark. The E. coli
was then washed for three times with PBS to remove free
FITC and resuspended in PBS. A 500μl of mixed bacterial
samplewaspreparedbyeasilymixing1.8×106 cells/mlFITC-
labeledE.coliand3.6×105 cells/mlunlabeledM.tuberculosis.
The mixture was detected with the FNP-IIFM method.
2.7. Preparationofspikedsputumsample
Sputum (2ml) from healthy individual was collected and
equally divided into two portions. One portion was spiked
with M. tuberculosis, whereas the other portion was used as
the unspiked sample. Then samples were liqueﬁed with the
NALC-NaOH method. In brief, the samples were mixed with
equal volumes of NALC-NaOH solution (2% NaOH, 1.45%
Na-citrate, and 0.5% NALC), shaken vigorously for diges-
tion, and the mixtures were allowed to stand for 15 minutes
at room temperature. Then the samples were diluted with
8ml of water. To remove big agglomerates in the sputum, the
mixtures were centrifuged at 1000rpm for 2 minutes. The
precipitates were disposed and the supernatants were cen-
trifugedat4000gfor15minutes.Afterthesupernatantﬂuids
were carefully decanted, the sediments were resuspended in
10ml of PBS and centrifuged again at 4000g for 15 minutes.
The supernatants were discarded. The resulting pellets were
suspended in 500μl of PBS and detected with the FNP-IIFM
method.
2.8. Microscopyimaging
An inverted ﬂuorescence microscope ECLIPSE TE300
(Nikon) equipped with a 100W mercury lamp, a ﬁl-
ter block (consisting of a 450–490nm bandpass excitation
and a 515nm longpass emission ﬁlter), and a color CCD
(Digital Camera DXM1200, Nikon) was used for com-
mon smear microscopic examination. Confocal microscopy
was performed on an inverted Olympus IX70 microscope
with an argon/krypton laser emitting at 488nm to ex-
cite both RuBpy-doped nanoparticles and FITC ﬂuores-
cence. We used a dichroic beam splitter (DCB) around
560nm, together with either a longpass (LP) 560nm ﬁl-
ter for RuBpy-doped nanoparticles signal or an LP 505nm
ﬁlter for FITC signal. The RuBpy-doped nanoparticles sig-
nal was displayed in the pseudocolor red and the FITC sig-
nal in green. To study the diﬀerentiation between M. tu-
berculosis and E. coli in mixed bacterial samples with the
FNP-IIFM method, the smears were scanned by sequen-
tial excitation mode. In brief, an argon/krypton laser emit-
ting at 488nm and a helium/neon laser emitting at 543nm
were used to excite FITC and RuBpy-doped silica nanopar-
ticles ﬂuorescence, respectively. We used a DCB around
560nm, together with the following emission ﬁlter: ei-
ther a bandpass (BP) 505–525nm when the argon/krypton
laser (FITC signal) was used or an LP 560nm when the
helium/neon laser (RuBpy-doped silica nanoparticles sig-
nal) was used. A ×60 objective (Olympus PlanApo NA 1.4
oil) was used for routine studies. Pixel format was 512 ×
512.
3. RESULTS AND DISCUSSION
3.1. Highlyluminescentandphotostable
ﬂuorescentnanoparticles
We used an easy and eﬃcient water-in-oil microemulsion
method to synthesize RuBpy-doped silica nanoparticles. The
obtained nanoparticles were uniform and well dispersed as
shown in the AFM image (Figure 1(a)). Dynamic light scat-
tering (DLS) measurements for the nanoparticles showed
that the size distribution of RuBpy-doped nanoparticles was
narrow and the volume-weighted mean hydrodynamic di-
ameter determined was 63.8nm (Figure 1(b)). For the struc-
ture of dye-doped silica nanoparticles, dye molecules are
trapped inside the silica matrix, which endows the nanopar-
ticles with two important merits. For one thing, the ﬂu-
orescence emitted by one nanoparticle is contributed by
thousands of dye molecules embedded in the silica ma-
trix. So it is easy to see that one dye-doped nanoparticle
is much more luminescent than one dye molecule, which
is called the signiﬁcant signal ampliﬁcation eﬀect. This at-
tribute makes the dye-doped nanoparticles be advantageous4 Journal of Biomedicine and Biotechnology
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Figure 1: Properties of RuBpy-doped silica nanoparticles. (a) AFM micrograph of the RuBpy-doped silica nanoparticles. Particle size is
determined to be 65 ± 2nm. (b) Size distribution analysis of RuBpy-doped silica nanoparticles in water by dynamic light scattering (DLS).
The volume-weighted average diameter determined is 63.8nm. (c) Photostability of RuBpy-doped silica nanoparticles versus pure RuBpy
dye molecules and FITC dye molecules. Realtime measurements of ﬂuorescence intensities were performed on an confocal microscope with
an intensive argon/krypton laser as the excitaton source.
M. tuberculosis
Surface antigen of M. tuberculosis
Protein A modiﬁed ﬂuorescence Nanoparticles
Speciﬁc antibody
Figure 2: Schematic representation of theprinciple of the detection
of M. tuberculosis with the ﬂuorescent nanoparticle-based indirect
immunoﬂuorescence assay.
in improving detection sensitivity in many aspects and very
suitable for detection of bacteria with higher sensitivity. As
another advantage, due to the protective function of the sil-
ica matrix, the nanoparticles are much more photostable
than ordinary dye molecules. As shown in Figure 1(c),a f -
ter continuous intensive illumination with a laser source for
80 seconds, the ﬂuorescence intensities of both RuBpy and
FITC dyes were decreased to below 20%, while the ﬂuo-
rescence intensiy of RuBpy-doped nanoparticles remained
above 80%.
3.2. CovalentimmobilizationofProtein
Aonnanoparticles
Covalent attachment of antibodies directly to solid supports
via glutaraldehyde, carbodiimide, succinimide ester, and so
forth is always found with the loss of biological activity of
the antibodies. One of the main reasons for such reduction
is attributed to the random orientation of the asymmetric
macromolecules on support surface [30]. Several approaches
for achieving oriented antibody coupling for good steric ac-
cessibilitiesofactivebindingsitesandincreasedstabilityhave
been developed, including the use of Protein A or Protein G
[31], chemical or enzymatic oxidation of the immunoglob-
ulin (IgG) carbohydrate moiety [32], and the use of biotin-
avidin or streptavidin techniques [33]. Protein A, a highly
stable 42kDa coat protein extracted from Staphylococcus au-
reus, is capable of binding to the Fc portion of immunoglob-
ulins, especially IgGs, from a large number of species [34]. In
our scheme, Protein A was used as an aﬃnitive adsorber to
avoid direct attachment of antibody to nanoparticles.
ForimmobilizationofProteinAontheRuBpy-dopedsil-
ica nanoparticles, the CNBr method was used to activate the
surface of silica nanoparticles and then couple the Protein A.
The surface coverage of Protein A on the nanoparticles was
quantiﬁed by the Bradford method, and the average mass of
one particle was determined through the viscosity/light scat-
tering method, then the number of Protein A molecules at-
tached to one particle could be calculated. The amount of
Protein A immobilized on nanoparticles was calculated ap-
proximately as [29]:
q =

Ci −Ct

V

m,( 1 )Dilan Qin et al. 5
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Figure 3: The speciﬁc, nonspeciﬁc interactions, and signal ampliﬁcation eﬀect of biocojugated nanoparticles interacted with bacteria. All
pictures were obtained with confocal microscopy (60 × oil), (a)–(e) transmission images, (f)–(j) ﬂuorescence images. (a), (f) M. tuberculosis
recognized with bioconjugated ﬂuorescent nanoparticles. The bacteria display a bright ﬂuorescence. (b), (g) Control with PBS in place of the
primary rabbit anti-M. tuberculosis antibody. No ﬂuorescence is associated with the bacteria. (c), (h) Control with rabbit anti-p53 antibody
in place of the primary rabbit anti-M. tuberculosis antibody. No ﬂuorescence is associated with the bacteria. (d), (i) E. coli incubated with
bioconjugated ﬂuorescent nanoparticles. No labeling of the bacteria with nanoparticle bioconjugates is observed. (e), (j) M. tuberculosis
recognized with FITC conjugated rabbit anti-M. tuberculosis antibody. The bacteria display a faint ﬂuorescence.
where q is the amount of Protein A immobilized onto a unit
mass of the nanoparticles (mg/mg); Ci and Ct are the con-
centrations of the Protein A in the initial solution and in the
supernatant after the immobilization reaction, respectively
(mg/ml); V is the volume of the aqueous phase (ml); and m
is the mass of the nanoparticles (mg). Ci and Ct were deter-
mined by the Bradford method [28]. The amount of Protein
A immobilized on nanoparticles calculated according to (1)
in our experiment was ∼0.41mg/mg. The average mass of
one particle was then determined and calculated as
mi = C/N,( 2 )
where mi is the average mass of one nanoparticle (mg); C is
the concentration of the nanoparticle suspension (mg/ml);
N is the number of nanoparticles in a unit volume of sus-
pension liquid (particles/ml), which was calculated through
the viscosity/light scattering method [35]a s
N = φ

4/3π(d/2)
3
,( 3 )
where 4/3π(d/2)
3 is the average volume of a nanoparticle; d
isthevolume-weighteddiameterdeterminedbylightscatter-
ing; and φ is the volume fraction of the particles determined
by viscosity and calculated as
φ =

h/h0 −1

2.5, (4)
where h is the viscosity of the nanoparticle suspension; h0 is
the viscosity of the solvent without nanoparticles. According
to (2)–(4), the average mass of one nanoparticle calculated
was ∼8.8×10
−17g. So there were ∼3.6×10
−14mg Protein A
on one particle, that is, ∼5.2 × 102 Protein A molecules on
one particle. It provided a foundation for optimal binding of
the nanoparticle-Protein A conjugates with the antibody in
the later process.
3.3. DetectionofM.tuberculosisinpureculture
A method of ﬂuorescent nanoparticle-based indirect im-
munoﬂuorescence microscopy (FNP-IIFM) was developed
for the rapid detection of Mycobacterium tuberculosis.T h e
principle for this method was illustrated in Figure 2. In this
scheme, M. tuberculosis was ﬁrst recognized by a rabbit anti-
M.tuberculosisantibodyandthenthenanoparticle-ProteinA
conjugateswereusedtogenerateﬂuorescentsignal.Toexam-
ine the binding of bioconjugated nanoparticles to bacteria,
the incubated bacteria were imaged using either ﬂuorescence
microscopy or confocal microscopy.
Pure M. tuberculosis suspension was ﬁrst immuno-
detected with the FNP-IIFM method and the resulting con-
f o c a li m a g e sw e r es h o w ni nF i g u r e s3(a), 3(f).T h eb a c t e -
ria displayed a bright ﬂuorescence. This indicated that large
quantities of nanoparticles had bound to the M. tuberculosis
cells.Inordertodemonstratewhetherthebindingofbiocon-
jugated nanoparticles to M. tuberculosis was solely through
the antigen-speciﬁc targeting pattern or there were other
nonspeciﬁc interactions between the Protein A-nanoparticle
conjugates and other surface molecules of the bacteria, two
controls were set in which the primary antibody was substi-
tuted with the following: (1) PBS only; (2) a rabbit anti-p536 Journal of Biomedicine and Biotechnology
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Figure 4: Detection of M. tuberculosis in mixed bacterial samples
withtheFNP-IIFMmethod.Amixturecontaining1.8×106 cells/ml
FITC-labeled E. coli and 3.6×105 cells/ml unlabeled M. tuberculosis
was detected. (a) Confocal microscopic images (60 × oil): (A) im-
age obtained after excitation with the 488nm laser and displayed in
the pseudocolor green (FITC signal); (B) image obtained after ex-
citation with the 543nm laser and displayed in the pseudocolor red
(RuBpy-doped nanoparticles signal); (C) overlay of the green chan-
nel and the red channel images; (D) transmission image. The con-
focal images show that there is no colocalization of the red ﬂuores-
cent nanoparticles with E. coli (green). (b) Truecolor ﬂuorescence
image (100 × oil) with an inverted ﬂuorescence microscope. Green:
FITC-labeled E. coli; Orange: bioconjugated ﬂuorescent nanoparti-
cles identiﬁed M. tuberculosis. The diﬀerentiation of M. tuberculosis
from E. coli in the mixture with the FNP-IIFM method is good.
antibody. No ﬂuorescence was observed to associate with the
M. tuberculosis in both controls as shown in Figures 3(b),
3(g) and 3(c), 3(h), suggesting that there was little nonspe-
ciﬁc interaction between the Protein A-nanoparticle conju-
gates and the M. tuberculosis cell wall. These results identify
that the bioconjugated nanoparticles bind to M. tuberculosis
throughtheantibody-mediatedantigenbindingpattern.An-
other bacterium E. coli DH5α was also tested with the FNP-
IIFM method. No labeling of the bacteria with the nanopar-
ticle bioconjugates was observed as shown in Figures 3(d),
3(i). The result shows that the anti-M. tuberculosis antibody
does not cross-react with E. coli DH5α, and the nanoparticle
bioconjugates do not attach to E. coli DH5α nonspeciﬁcally,
which indicates that the FNP-IIFM method can be used to
detect Mycobacterium tuberculosis in pure culture.
The ﬂuorescence enhancement capability of the biocon-
jugatednanoparticleslabelintheFNP-IIFMmethodhasalso
been investigated. The detection of M. tuberculosis with bio-
conjugated RuBpy-doped nanoparticles was compared with
the commercial FITC conjugated rabbit anti-M. tuberculosis
antibody. The ﬁnal antibody concentration used in the FITC
method was 25μg/ml. It was 5-fold higher than that used
in the FNP-IIFM method. We used higher concentration of
antibody in the FITC method because the induced ﬂuores-
cence signal was too low when the antibody concentration
was 5μg/ml. Figures 3(e), 3(j) showed the confocal images
of M. tuberculosis recognized by the FITC method. The ﬂu-
orescence signal from the bacteria recognized with the FITC
method (Figure 3(j)) was much weaker than the signal with
the FNP-IIFM method (Figure 3(f)). Although the primary
antibody used in the FNP-IIFM method was only one ﬁfth
of that used in the FITC method, the average ﬂuorescence
intensity of M. tuberculosis recognized with the FNP-IIFM
method was determined to be above ﬁve times of that with
the FITC method. The experiment reveals the signal advan-
tage that the ﬂuorescent nanoparticles possess over conven-
tional ﬂuorescent dye.
3.4. DetectionofM.tuberculosisin
mixedbacterialsamples
ToevaluatethedetectioncapabilityoftheFNP-IIFMmethod
in complex samples, artiﬁcial complex samples consisting of
M. tuberculosis and E. coli were used for test. In order to
estimate the accuracy of the detection with the FNP-IIFM
method in bacterial mixture, E. coli was labeled with FITC
to distinguish from M. tuberculosis prior to the detection.
Then the FITC-labeled E. coli was mixed with unlabeled M.
tuberculosis to constitute the mixed bacterial samples and
detected with the FNP-IIFM method. The results obtained
with confocal microscopy were shown in Figure 4(a).T h e
image in Figure 4(a)-A showed the FITC ﬂuorescence asso-
ciated with E. coli in the mixture (pseudocolor green, emis-
sion ﬁlter: BP 505-525nm). Figure 4(a)-B showed the ﬂu-
orescence of the bioconjugated RuBpy-doped nanoparticles
which had bound to bacteria (pseudocolor red, emission ﬁl-
ter: LP 560nm). If the nanoparticles also attached to E. coli,
the ﬂuorescence would appear yellow in the overlay image
(the combination of green plus red). The overlay image in
Figure 4(a)-Cshowednocolocalizationoftheredﬂuorescent
nanoparticles with E. coli, so the bioconjugated nanoparti-
cles only bound to the M. tuberculosis. Besides, the detec-
tion was also observed with the less-expensive ﬂuorescence
microscopy. As shown in Figure 4(b), the diﬀerentiation of
M. tuberculosis from E. coli with the FNP-IIFM method wasDilan Qin et al. 7
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Figure 5: Photostability comparing of the ﬂuorescent nanoparticles labeled on M. tuberculosis and FITC dyes labeled on E. coli. Am i x t u r e
containing 1.8 ×106 cells/ml FITC-labeled E. coli and 3.6 ×105 cells/ml unlabeled M. tuberculosis was detected with the FNP-IIFM method.
The slide was successive irradiated with an intensive argon/krypton laser under the confocal microscope (60 × oil) for (a) and (b) 0 second,
(c) 1 minute, (d) 2 minutes, (e) 4 minutes, (f) 6 minutes. (a) Transmission image, (b)–(f) Fluorescence images. Green: E. coli;R e d :M.
tuberculosis. The ﬂuorescence of FITC was dim after being continuously irradiated for 2 minutes while that of the nanoparticles was still
bright.
good. These results indicate that the FNP-IIFM method can
be used to detect M. tuberculosis in mixed bacterial sam-
ples.
Meanwhile, the photostability of the ﬂuorescent label in
the FNP-IIFM method was also investigated. We compared
the photostability of RuBpy-doped nanoparticles bound on
M. tuberculosis and FITC dyes labeled on E. coli. The ﬂuores-
cence of FITC was dim after being continuously irradiated
for 2 minutes while that of the nanoparticles was still bright,
as shown in Figure 5. It is demonstrated that the biocon-
jugated RuBpy-doped silica nanoparticles used in the FNP-
IIFM method possess much better photostability in compar-
ison with the FITC dye label.
3.5. DetectionofM.tuberculosisinspikedsputum
In order to demonstrate the usefulness of our method for M.
tuberculosis detection under clinical condition, M. tuberculo-
sis was spiked into sputum and detected with the FNP-IIFM
method. The result was compared with unspiked sputum
control to make certain whether the M. tuberculosis could
be detected in the sputum. Sputum from healthy individ-
ual was collected and equally divided into two portions. One
portion was spiked with M. tuberculosis, whereas the other
portion was used as the unspiked sample. The spiked sample
and unspiked sample were parallelly pretreated and detected
by the FNP-IIFM method. For sample pretreatment, we used
the NALC–NaOH method to liquefy the sputum. After liq-
uefaction for 15 minutes, the viscosity of the sputum was
greatly decreased. However, there were some visible big ag-
glomerates in both the spiked and unspiked sputum which
could neither be liqueﬁed nor be brokenup by vigorously
vortexing. These big agglomerates caused poor smear quality
such as uneven thickness, and had better been removed be-
fore immuno-reaction. To remove the big agglomerates, we
centrifuged the liqueﬁed sputum samples at low centrifugal
speed (1000rpm, 2 minutes) and disposed the precipitates.
The supernatants were detected with the FNP-IIFM method.
As we expected, the sputum samples were much complex
mixtures containing a great deal of bacteria and impurities
shown in Figure 6. In the unspiked sputum sample, no ﬂuo-
rescentbacteriumwasfoundasshowninFigure 6(b).Itindi-
catesthatthebioconjugatednanoparticleshavelittlenonspe-
ciﬁc interaction with the sputum components and the oral
bacteria. In the spiked sputum sample, we found highly lu-
minescent bacteria in many microscopic ﬁelds as shown in
Figure 6(a) (the luminescent bacterium indicated by the ar-
row). By comparing with the unspiked sample, the lumines-
cent bacteria were considered to be M. tuberculosis recog-
nized by the bioconjugated nanoparticles. The high intensity
of ﬂuorescence associated with the recognized M. tuberculo-
sis well distinguished the object bacteria from the complex
background. The time needed to ﬁnish detecting M. Tuber-
culosis with the FNP-IIFM method in sputum is <4h o u r s
after the receipt of specimen (sample pretreatment: <1h o u r ,
immunoassay and smear examination: <3h o u r s ) .Th i sr e s u l t
demonstrates that our FNP-IIFM method is useful for rapid
detection of M. tuberculosis in sputum.8 Journal of Biomedicine and Biotechnology
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Figure 6: Detection of M. tuberculosis in spiked sputum. M. tuber-
culosis spiked sputum and unspiked sputum control were detected
with the FNP-IIFM method after pretreatment with the NALC-
NaOH method. Both images were overlay of the ﬂuorescence chan-
nel and the trasmitted channel of confocal images (60 × oil). (a)
Sputum spiked with M. tuberculosis. Note that a bacterium displays
bright ﬂuorescence, indicated by the arrow. (b) Unspiked sputum.
No ﬂuorescent bacterium is found.
4. CONCLUSIONS
We have developed a new method for the detection of M. tu-
berculosis using ﬂuorescent nanoparticle-based indirect im-
munoﬂuorescence microscopy. With this method, M. tu-
berculosis can be detected in both mixed bacterial samples
and sputum samples. Total assay time including sample pre-
treatment is within 4 hours. Comparing with conventional
ﬂuorescent dyes, the use of ﬂuorescent nanoparticles as la-
bel in immunoﬂuorescence microscopy oﬀe r sa d v a n t a g e so f
higher luminescence and higher photostability. This method
can integrate with epiﬂuorescent ﬁlter techniques to further
shorten the time needed for detection. In addition, by sub-
stituting the antibody to suit to other bacteria, this technique
has the potential to develop to a universal method for detect-
ing a wide variety of bacteria in biomedical and biotechno-
logical areas.
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